Equities

Adimmune Corp

4142:TAI

Adimmune Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)24.10
  • Today's Change-0.25 / -1.03%
  • Shares traded699.35k
  • 1 Year change-25.73%
  • Beta--
Data delayed at least 20 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of TWD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,4702,9732,891
Total Receivables, Net1,308535100
Total Inventory526659506
Prepaid expenses282297274
Other current assets, total1132726
Total current assets4,6994,4913,796
Property, plant & equipment, net3,9763,8483,575
Goodwill, net------
Intangibles, net7093117
Long term investments133127145
Note receivable - long term335327137
Other long term assets423512
Total assets9,4849,1498,010
LIABILITIES
Accounts payable42495.88
Accrued expenses------
Notes payable/short-term debt540200
Current portion long-term debt/capital leases68514248
Other current liabilities, total520290243
Total current liabilities1,787500297
Total long term debt1,9182,1011,273
Total debt3,1432,2631,321
Deferred income tax------
Minority interest303421284
Other liabilities, total1.942.357.95
Total liabilities4,0103,0251,861
SHAREHOLDERS EQUITY
Common stock4,2954,2954,295
Additional paid-in capital835849855
Retained earnings (accumulated deficit)5981,238945
Treasury stock - common(293)(293)--
Unrealized gain (loss)393554
Other equity, total------
Total equity5,4756,1246,149
Total liabilities & shareholders' equity9,4849,1498,010
Total common shares outstanding422422430
Treasury shares - common primary issue8.008.000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.